Research programme: asthma therapy - OSI Pharmaceuticals

Drug Profile

Research programme: asthma therapy - OSI Pharmaceuticals

Alternative Names: Asthma therapy research programme - OSI Pharmaceuticals

Latest Information Update: 30 Jun 2006

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Class
  • Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 30 Jun 2006 No development reported - Preclinical for Asthma in USA (unspecified route)
  • 26 Jun 2002 This programme is still in active development
  • 25 Feb 2000 Preclinical development for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top